NNDM

Nano Dimension and Infinite Epigenetics have issued a joint release providing additional details on Infinite's business model, market opportunity, and capital plan related to their proposed business combination. The release also serves as a response to a letter from activist investor Murchinson Ltd., which has apparently raised objections or questions about the deal. No new financial terms or revised deal structure were disclosed in this update.

Nano Dimension (NNDM) has signed a non-binding term sheet for a proposed business combination with Infinite Epigenetics, a private AI-powered preventive health and diagnostics company. The deal would result in a publicly traded entity leveraging Infinite Epigenetics' proprietary biological AI platform focused on epigenetic signals. The term sheet is non-binding, meaning the transaction is not yet confirmed and remains subject to further negotiation and approvals.